

VGI Health Technology Limited – Ethics Approval Received for US Pharmacokinetics and Exercise Clinical Study

Sydney, New South Wales, 26 September 2022 – VGI Health Technology Limited (**NSX:VTL**) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (**Invictus**), has received ethics approval to proceed with a US pharmacokinetics and exercise clinical study.

Institutional Review Board (**IRB**) approval was received by **Invictus**' research partner, Altipure R&D in Ohio, USA, to conduct a clinical study comprising 45 healthy volunteers to assess the bioavailability of delta tocotrienols (**DT3**) which have been administered via **Invictus**' transmucosal delivery platform. The study will also measure exercise performance and muscle power for two doses of **Invictus**' exercise performance nutraceutical product NE1-Elite® along with other endpoints such as lactate, glucose and lipids in the blood. Changes in muscle and fat mass will also be measured.

This clinical study will be led by VTL's Scientific Advisory Board Member Dr Jordan Moon, who said "We have seen some really exciting results which suggest that **Invictus**' transmucosal delivery platform can accommodate a far wider range of dosages than we had previously thought was possible. Now we want to see whether multiple higher doses administered over a period of time will translate to improvements in exercise performance".

Previously on 21 March 2022, **Invictus** reported on a clinical study led by Dr Moon showed that administering a single 80mg dose of **DT3** via **Invictus**' transmucosal delivery resulted in plasma concentrations which were more than double those achieved with a 40mg dose. The present study will investigate the effect of transmucosal administration of multiple doses of **DT3** over a period of 3 weeks.

Dr Glenn Tong, the CEO and Managing Director of VTL, said "While it is never wise to attempt to predict the results of a clinical study, we are quietly confident that data generated from Dr Moon's study will open up a great opportunity for new products both in our nutraceuticals and pharmaceuticals pipeline."

For more information please contact:

Dr Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Mrs Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:
https://www.nsx.com.au/broker_list_print.asp